Gene content    
FGFR2 ( by HUGO)
Fibroblast Growth Factor Receptor
Oncogene
Fibroblast Growth Factor Receptor 2
BEK
Keratinocyte Growth Factor Receptor
KGFR
CFD1
JWS
Bacteria-Expressed Kinase
FGFR-2
EC 2.7.10.1
BBDS
TK14
Craniofacial Dysostosis 1
Crouzon Syndrome
Jackson-Weiss Syndrome
Pfeiffer Syndrome
BFR-1
CD332
CEK3
ECT1
K-SAM
TK25
BEK Fibroblast Growth Factor Receptor
FGF Receptor
FGFR2-AHCYL1 Fusion Kinase Protein
Hydroxyaryl-Protein Kinase
Protein Tyrosine Kinase
Receptor Like 14
Soluble FGFR4 Variant 4
K-sam
KSAM
CD332 Antigen
EC 2.7.10
NCBI: 10q26    Ensembl: 10q26.13
FGFR2_HUMANSize: 821 amino acidsMass: 92025 Da

  • Subunit: Monomer. Homodimer after ligand binding. Interacts predominantly with FGF1 and FGF2, but can also interact with FGF3, FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). Ligand specificity is determined by tissue-specific expression of isoforms, and differences in the third Ig-like domain are crucial for ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, and has much higher affinity for FGF7 than isoform 1 (in vitro). Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 and PAK4 Sequence caution: Sequence=BAG57383.1; Type=Erroneous initiation; Note=Translation N-terminally shortened; Selected PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for FGFR2 (see all 33): 1DJS (3D) [IMAGE] 1E0O (3D) [IMAGE] 1EV2 (3D) [IMAGE] 1GJO (3D) [IMAGE] 1II4 (3D) [IMAGE] 1IIL (3D) [IMAGE]
  • Function:
    Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1
                          
    Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1
  • Catalytic activity:
    ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
  • Similarity:
    Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily
                          
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains
                          
    Contains 1 protein kinase domain [IMAGE]
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR000719Prot_kinase_domProtein kinaseDomain
    IPR001245Ser-Thr/Tyr_kinase_cat_domTyrosine protein kinaseDomain
    IPR003598Ig_sub2Immunoglobulin C2 typeDomain
    IPR007110Ig-like_domImmunoglobulin-likeDomain
    IPR008266Tyr_kinase_ASTyrosine protein kinase, active siteActive Sites
    IPR011009Kinase-like_domProtein kinase-likeDomain
    IPR013098Ig_I-setImmunoglobulin I-setDomain
    BlocksIPB003598Immunoglobulin C-2 typeImmunoglobulin C-2 type
    IPB008266Tyrosine protein kinaseTyrosine protein kinase, active site

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process embryonic cranial skeleton morphogenesis IMP GOA 7874170
    fibroblast growth factor receptor signaling pathway IPI GOA 10830168
    fibroblast growth factor receptor signaling pathway IGI GOA 8663044
    fibroblast growth factor receptor signaling pathway IDA GOA 15629145
    peptidyl-tyrosine phosphorylation IDA GOA 15629145
    positive regulation of cell proliferation IMP GOA 15629145
    positive regulation of cell proliferation IGI GOA 8663044
    positive regulation of cell proliferation IDA GOA 8663044
    positive regulation of MAPK cascade IMP GOA 15629145
    positive regulation of phospholipase activity IMP GOA 16844695
    protein autophosphorylation IDA GOA 15629145
    regulation of osteoblast differentiation TAS GOA 15190072
    regulation of osteoblast proliferation TAS GOA 15190072
    skeletal system morphogenesis TAS GOA 15190072
    Cellular Component cell cortex IDA GOA 17471512
    cell surface IDA GOA 16597614
    colocalizes_with extracellular matrix IDA GOA 17959718
    cytoplasm IDA GOA 16597614
    integral component of membrane NAS GOA 1697263
    integral component of plasma membrane IDA GOA 15629145
    membrane NAS GOA 8676562
    Molecular Function fibroblast growth factor binding IPI GOA 11923311
    fibroblast growth factor binding IDA GOA 8663044
    fibroblast growth factor-activated receptor activity NAS GOA 1400433
    fibroblast growth factor-activated receptor activity IGI GOA 10830168
    fibroblast growth factor-activated receptor activity IDA GOA 15629145
    protein binding IPI GOA 10618369
    protein homodimerization activity IPI GOA 16844695
    protein tyrosine kinase activity NAS GOA 1697263

    Disorder & Mutation    
    Source Disease
    SWISS-PROTBeare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An autosomal dominant disease characterized by craniofacial anomalies, particularly craniosynostosis, and ear defects, cutis gyrata, acanthosis nigricans, anogenital anomalies, skin tags, and prominent umbilical stump. The skin furrows have a corrugated appearance and are widespread. Cutis gyrata variably affects the scalp, forehead, face, preauricular area, neck, trunk, hands, and feet. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTPfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3). Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTApert syndrome (APRS) [MIM:101200]: A syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTJackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTCrouzon syndrome (CS) [MIM:123500]: An autosomal dominant syndrome characterized by craniosynostosis, hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTFamilial scaphocephaly syndrome (FSPC) [MIM:609579]: An autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTLacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]: An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTAntley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported. Note=The disease is caused by mutations affecting the gene represented in this entry

    FGFR2 cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene